The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzimidazoles / agonists
  • Benzimidazoles / pharmacology*
  • Cell Line, Tumor
  • Drug Synergism
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / pathology
  • Proteasome Inhibitors / pharmacology*
  • Signal Transduction / drug effects*

Substances

  • Benzimidazoles
  • Histone Deacetylase Inhibitors
  • Proteasome Inhibitors
  • tinostamustine